이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

난치성 MGD에서 비침습적 RF 치료의 치료 효능 및 안전성

2026년 11월 5일 업데이트: The University of Hong Kong

불응성 마이봄선 기능 장애 환자에서 비침습적 고주파 치료의 치료 효능 및 안전성: 무작위 대조 시험

The goal of this prospective, 24-week, double-masked, randomized, sham-controlled clinical trials to compare clinical efficacy and safety of RF and MGX with MGX alone in patients with meibomian gland dysfunction-related dry eye disease. The main question it aims to answer is whether radiofrequency treatment and meibomian gland expression is more effective in improving tear breakup time, as measured using non-invasive video keratography, compared with meibomian gland expression alone, in patients with refractory meibomian gland dysfunction-related dry eye disease.

Participants will be divided into two groups, one group will receive RF treatment followed with MGX and another will receive sham treatment with MGX.

연구 개요

상태

모병

정황

개입 / 치료

상세 설명

Dry eye disease(DED) is a prevalent age-related ophthalmic condition. Depending on the population studied and the diagnostic criteria used, dry eye disease is estimated to have a high prevalence in most populations , with a female preponderance. In the latest 2017 Tear Film and Ocular Surface Society Dry Eye Workshop II (TFOS DEWS II) Epidemiology Report, which compiled dry eye prevalence data from studies worldwide, the reported the prevalence of DED ranged from 5 to 50%. The risk of dry eye disease increases with age, where with every increase in 10 years of age, the self-reported symptoms of DED increased by 2%. In one study in Asia, up to 70% of elderly patients greater than 60 years of age suffering from symptomatic dry eye disease. Dry eye disease causes gritty and painful eyes, with associated blurred vision. For sufferers, it poses a significant burden on quality of life and limitations activities on activities of daily living, resulting in considerable economic costs to society. A 2006 health-economics study in the United Kingdom estimated that the annual healthcare costs to the public sector for every 1000 dry eye patients was USD 1.1 million.

The causes of dry eye can be broadly classified into those with aqueous tear deficiency, excessive tear evaporation or a combination of both. The most common cause of excessive tear evaporation is meibomian gland dysfunction (MGD). This is a common condition of the eyelids where there is a significant change in both the consistency and quantity of meibum, resulting in chronic inflammation of the eyelids and subsequent ocular surface dysfunction. MGD has a prevalence from 46.2% to 69.3% in several studies targeting Asian populations, with a trend of higher prevalence in the elderly. Insufficient lipid secretion from meibomian gland undermines tear film stability, producing dry eye symptoms despite normal tear secretion. In a recent study, up to 70.3% of dry eye patients were found to have concurrent MGD. Refractory MGD is defined by the failure to respond to more than at least three types of conventional therapy, including lubricating eyedrops, gels and ointments and topical or systemic anti-inflammatory treatment, in the past two years.

Currently heat-based therapies are the mainstay and most effective strategies against MGD. Eyelid warming, thermal pulsation and intense light therapy are three prevailing heat-based treatments for MGD- related dry eye disease. Eyelid warming usually involves the application of warm towels, commercialized eye masks (EyeGiene® or Blephasteam®) or eye bags (MGDRx Eye Bag) at least twice a day. Thermal pulsation (Lipiflow®) refers to the delivery of controlled heat together with gentle massage to the eyelids by the machine for 10-17 minutes. Intense pulsed light (IPL) therapy, which uses light energy on the skin surface, is widely used in dermatology to treat a variety of conditions including dermal vascular lesions, such as port wine stains and hemangiomas, facial rosacea, and acne. Each treatment strategy however carries significant limitations. Self-applied eyelid warm compress is cheap and easily available, but when used alone has limited efficacy. Furthermore, sustained patient adherence to treatment is difficult long term. A single treatment of thermal pulsation therapy has been shown to have sustained therapeutic effects up to 12 months after treatment. However, thermal pulsation is not effective in moderate to severe cases of MGD. From existing studies, IPL has greater clinical efficacy than thermal pulsation, but its therapeutic effects are maintained for a significantly shorter period. As such, monthly repeated treatments for up to 8 months may be required for sustained effects. It is also important to note that none of the existing treatments allow the eyelids to evacuate inspissated meibum effectively, with meibum expression by an ophthalmologist an important step in the treatment process. Thus, MGD is likely to recur long-term.

The Thermage FLX System (WA, USA) is a non-ablative radiofrequency (RF) energy-based device, which has been widely adopted in the cosmetic industry for radiofrequency tissue tightening. RF transfers high energy fluences through the skin to deep dermal layers uniformly while protecting the epidermis. It is postulated that RF stimulates subdermal collagen production for tissue tightening effect. There are several advantages of using non-invasive RF treatment over other currently available energy-based devices. Firstly, the Thermage FLX has a much more precise applicator directly targeting the meibomian glands. Thermage FLX addresses both the upper and lower eyelids as close as possible to the lid margin, which is directly where the meibomian glands are situated, it also addresses the tragus area as well, hence a more precise and direct treatment area can be achieved. Secondly, compared to other energy-based devices, Thermage FLX provides a higher accumulative heat transfer effect around the periocular region, due to its repeated application of at least 4-5 cycles around the periorbital region. With higher accumulative heat energy, we anticipate a better and more effective melting of the meibum, which aids in more effective meibum expression. Thirdly, as Thermage FLX has been widely adopted for radiofrequency tissue tightening due to its collagen resynthesis effect, there has been proven improvement of the elasticity of orbicularis and periocular skin tissue, this can promote better blinking effort and better apposition of lid margins. This may enhance the pumping effect of the orbicularis oculi in the long-term. RF treatment is potentially a safe and effective multimodal treatment for MGD-related dry eye disease.

연구 유형

중재적

등록 (추정된)

112

단계

  • 해당 없음

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 연락처

  • 이름: Kendrick Co SHIH
  • 전화번호: 94326271
  • 이메일: kcshih@hku.hk

연구 장소

      • Hong Kong, 홍콩
        • 모병
        • HKU Eye Centre
        • 연락하다:
          • Kendrick Co SHIH
          • 전화번호: 94326271
          • 이메일: kcshih@hku.hk
    • Hong Kong
      • Hong Kong, Hong Kong, 홍콩
        • 모병
        • Grantham Hospital
        • 연락하다:
          • Kendrick Co Shih

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

18년 이상 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

설명

Inclusion Criteria:

  1. Age 18 or more
  2. Bilateral dry eye disease as confirmed by presence of both symptoms and signs 2.1 Symptoms: Abnormal result on the Standard Patient Evaluation of Eye Dryness Questionnaire (SPEED) dry eye symptom questionnaire (≥5) 2.2 Signs: Abnormal result in at least one of the following three clinical tests - tear osmolarity, NIKBUT and corneal staining for punctate epithelial erosions and,
  3. Bilateral moderate to severe meibomian gland dysfunction - at least Grade 1 meibum quality (cloudy appearance) and Grade 2 meibum expressibility (moderate pressure required). And,
  4. Refractory MGD - The failure to respond to at least three types of conventional therapy, including artificial tears, topical or systemic antibiotics and anti-inflammatory treatments and the aforementioned heat-based therapies, over a period of at least 2 years
  5. Fitzpatrick skin type I-IV - Type V and VI skinned subjects are excluded from the study due to the high risk of pain and focal hypopigmentation
  6. Mentally fit to give informed consent

Exclusion Criteria:

  1. Fitzpatrick skin type V-VI
  2. History of eyelid scarring
  3. Infrared meibography evidence of significant acinar gland atrophy (dropout of >30%) - these patients have been shown not to benefit from heat-based therapies due to end-stage disease
  4. Pregnancy or lactation
  5. Active corneal disease such as infectious keratitis, allergic keratoconjunctivitis, pterygium, exposure keratopathy, lagophthalmos, trichiasis or dellen
  6. Current systemic intake of photosensitive medications, including tetracycline group of drugs.
  7. History of corneal abnormality or surgery within 3 months

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 무작위
  • 중재 모델: 병렬 할당
  • 마스킹: 더블

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: Radiofrequency treatment (RF), followed by meibomian gland expression (MGX)

Before treatment, a thermage return pad will be applied to subject's skin to help prevent electrical burns. The return pad is a rubber, non-active electrode that creates a return path for radiofrequency energy back to the thermage comfort pulse technology (CPT) system. The upper and lower lid of both eyes are marked with skin marking paper (Thermage ® Skin Marking Paper TK-3.00). Coupling fluid is then applied to the external surface of the upper and lower lids of both eyes. All subjects then receive 225 applications to each eye over the upper and lower eyelids. Immediately after treatment, meibomian gland expression will be performed on both upper and lower eyelids of each eye for both eyes of all subjects using meibum expression forceps. Pain is minimized during this procedure by topical application of 0.4% oxybuprocaine hydrochloride.

The Thermage FLX System is tested for its therapeutic efficacy and safety on treating refractory Meibomian Gland Dysfunction

가짜 비교기: Sham treatment, followed by meibomian gland expression (MGX)

The training mode is used in the Thermage FLX, which simulates treatment without dissipation of radiofrequency energy. Immediately after treatment, meibomian gland expression will be performed on both upper and lower eyelids of each eye for both eyes of all subjects using meibum expression forceps. Pain is minimized during this procedure by topical application of 0.4% oxybuprocaine hydrochloride.

Sham treatment acts as a control to test the therapeutic efficacy and safety of The Thermage FLX System

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Change in non-invasive keratographic tear breakup time (NIKBUT)
기간: From baseline to 6 months post- treatment between study groups

NIKBUT is measured in seconds and average of 3 consecutive readings is taken. Higher values mean better outcomes.

From baseline to 6 months post- treatment between study groups

2차 결과 측정

결과 측정
측정값 설명
기간
Change in Standard Patient Evaluation of Eye Dryness (SPEED) symptom score
기간: From baseline to 6 months post-treatment between study groups

One number was collected per patient, with higher scores meaning worse outcomes

From baseline to 6 months post-treatment between study groups
Percentage of subjects with normal non-invasive keratographic tear breakup time (NIKBUT)
기간: 6 months

> 10 seconds, with lower scores meaning worse

6 months
Percentage of subjects with normal SPEED
기간: 6 months

<5, with higher scores meaning worse

6 months
Change in best corrected visual acuity
기간: from baseline to 6 months post-treatment

from logmar(1.0 to -0.1)

from baseline to 6 months post-treatment
Incidence of periorbital pain
기간: 6 months

at least 3/10 and above, with higher scores meaning worse

6 months
Incidence of ocular adverse events
기간: 6 months

evidence of uveitis, conjunctivitis, scleritis/episcleritis, new lens opacities, new cornea opacities

6 months
Incidence of non-ocular adverse events
기간: 6 months

eyelid skin burn, eyelid redness, eyelid hyper/hypopigmentation

6 months

기타 결과 측정

결과 측정
측정값 설명
기간
Change in cornea staining (National Eye Institute Grading System)
기간: from baseline to 6 months post-treatment

This serves as an objective parameter for ocular surface damage, with higher scores meaning worse

from baseline to 6 months post-treatment
Tear osmolarity
기간: from baseline to 6 months post-treatment

This serves as an objective parameter for ocular surface damage

from baseline to 6 months post-treatment
Change in Shirmer's I test reading
기간: from baseline to 6 months post-treatment

In millimetres. Readings serve as objective parameters for tear volume

from baseline to 6 months post-treatment
Tear meniscus height
기간: from baseline to 6 months post-treatment

In millimetres. Readings serve as objective parameters for tear volume

from baseline to 6 months post-treatment
Changes in meiboscore
기간: from baseline to 6 months post-treatment between study groups

These readings serve as parameters for meibomian gland dysfunction

from baseline to 6 months post-treatment between study groups
Changes in meibum expressibility
기간: from baseline to 6 months post-treatment between study groups

These readings serve as parameters for meibomian gland dysfunction, with higher scores meaning worse

from baseline to 6 months post-treatment between study groups
Changes in meibum quality
기간: from baseline to 6 months post-treatment between study groups

These readings serve as parameters for meibomian gland dysfunction, with higher scores meaning worse

from baseline to 6 months post-treatment between study groups

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

스폰서

수사관

  • 수석 연구원: Kendrick Co SHIH, The University of Hong Kong, Grantham Hospital

간행물 및 유용한 링크

연구에 대한 정보 입력을 담당하는 사람이 자발적으로 이러한 간행물을 제공합니다. 이것은 연구와 관련된 모든 것에 관한 것일 수 있습니다.

일반 간행물

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2024년 10월 22일

기본 완료 (추정된)

2027년 10월 30일

연구 완료 (추정된)

2027년 12월 31일

연구 등록 날짜

최초 제출

2023년 12월 10일

QC 기준을 충족하는 최초 제출

2024년 1월 22일

처음 게시됨 (실제)

2024년 1월 24일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 11월 9일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 11월 5일

마지막으로 확인됨

2026년 11월 1일

추가 정보

이 연구와 관련된 용어

기타 연구 ID 번호

  • 11221686

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

아니

미국 FDA 규제 기기 제품 연구

예

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .